Fig. 2.

Maximum intensity projection (MIP) ¹⁸F-FDG PET/CT images of a stage IV melanoma patient before onset of treatment (a), after two cycles of ipilimumab (b) and shortly after the end of the four-cycle treatment (c). The patient was characterized as SMD (MB) according to PERCIMT. Based on her clinical status, the patient was characterized as demonstrating SD, thus, clinical benefit (CB). PET/CT assessed by PERCIMT proved to be predictive of the patient’s clinical response. On the other hand, changes in ¹⁸F-FDG uptake and kinetics were rather inconclusive of the patient’s clinical outcome